News | June 08, 2022
ANG Lifesciences India Q4 FY 22 net profit soars to Rs. 5.28 Cr
The company has posted net profit of Rs.39.71 crores for the Financial Year ended March 31, 2022.
The company has posted net profit of Rs.39.71 crores for the Financial Year ended March 31, 2022.
Efgartigimod is approved in the United States as VYVGART for the treatment of adults with generalized myasthenia gravis
TLANDO was approved by the U.S. Food and Drug Administration (FDA) on March 28, 2022.
The drug will be manufactured at the group’s topical facility at Ahmedabad
The company has launched indigenously produced Dual Chamber Bags of global standards in India at a pocket-friendly price
Innate to receive $5M milestone payment from AstraZeneca
RH Capital, a leading women's health venture capital fund, announced three new investments to improve health outcomes for women in the US.
Norliqva was approved by the FDA on February 24, 2022 and is now available through normal retail distribution.
Taiyin Yang, PhD, Executive Vice President, Pharmaceutical Development and Manufacturing to Retire After 29 Years at Gilead
PAYBACK loyalty will be live in 4500 Apollo Pharmacy outlets across India
Subscribe To Our Newsletter & Stay Updated
